Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62(1):10-29
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Dreno B, Hauschild A, DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resectedstage III melanoma. J Clin Oncol 2011;29(Suppl):abstract TPS232
   Google Scholar
• Davar D, Tarhini A, Kirkwood JM. Adjuvant therapy: melanoma. J Skin Cancer 2011;2011:274382
   PubMedGoogle Scholar
• Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102(7):493-501
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996;14(1):7-17
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK, High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18(12):2444-58
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA, High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19(9):2370-80
   PubMed Web of Science ®Google Scholar
• Tannir NM, Cohen L, Wang X, Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006;107(9):2254-61
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10(21):1451-8
   PubMed Web of Science ®Google Scholar
• Glue P, Fang JW, Rouzier-Panis R, Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000;68(5):556-67
   PubMed Web of Science ®Google Scholar
• Bukowski R, Ernstoff MS, Gore ME, Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002;20(18):3841-9
   PubMed Web of Science ®Google Scholar
• Daud AI, Xu C, Hwu WJ, Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 2010;67(3):657-66
   PubMed Web of Science ®Google Scholar
• Xu C, Daud AI, DeConti RC, Comparisons of pharmacokinetic profiles of high dose interferon-alpha2b (IFNalpha-2b) and peginterferon-alpha2b (PegIFNalpha-2b) in melanoma patients. Poster presented at the 38th Annual Meeting of the American College of Clinical Pharmacology; September 13 – 15; San Antonio, TX, USA; 2009
   Google Scholar
• Eggermont AM, Suciu S, Santinami M, Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372(9633):117-26
   PubMed Web of Science ®Google Scholar
• Grob JJ, Jouary T, Dreno RGB, Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial. J Clin Oncol 2010;28(18 Suppl):abstract LBA8506
   Web of Science ®Google Scholar
• Eggermont AM, Suciu A, Santinami M, EORTC 18991 phase III trial: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up. J Clin Oncol 2011;29(Suppl):abstract 8506b
   Google Scholar
• Schering-Plough Corp. Oncologic drugs advisory committee meeting briefing book: PegIntron (pegylated interferon alfa-2b) as adjuvant treatment of stage III melanoma 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM184002.pdf [Cited 12 July 2011]
   Google Scholar
• Hauschild A, Weichenthal M, Rass K, Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 2010;28(5):841-6
   PubMed Web of Science ®Google Scholar
• Hauschild A, Gogas H, Tarhini A, Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008;112(5):982-94
   PubMed Web of Science ®Google Scholar
• Bottomley A, Coens C, Suciu S, Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009;27(18):2916-23
   PubMed Web of Science ®Google Scholar
• Dixon S, Walters SJ, Turner L, Hancock BW. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006;94(4):492-8
   PubMed Web of Science ®Google Scholar
• Cole BF, Gelber RD, Kirkwood JM, Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996;14(10):2666-73
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. SYLATRON™ (peginterferon alfa-2b) for injection, for subcutaneous use. 2001. Available from: http://www.merck.com/product/usa/pi_circulars/s/sylatron/sylatron_pi.pdf [Cited 6 July 2011]
   Google Scholar
• Dummer R, Mangana J. Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. Biologics 2009;3:169-82
   PubMedGoogle Scholar
• Merck & Co., Inc. Product information INTRON® A (interferon alfa-2b, recombinant for injection). 2008. Available from: http://www.spfiles.com/piintrona.pdf [Cited 6 July 2011]
   Google Scholar